Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Timolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timolol SCHEMBL2553603 | 1.00 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL4912 | 1.00 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL1587691 | 1.00 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL8858736 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL5539013 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL11418545 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL16094075 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL2356059 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL7591293 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL8858730 | 0.99 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843246-A | Methods and compositions for treating hemangiomas | 吉利斯麦金德研究院 | 2023-03-24 | — | — | CN | claimed |
| US-20230090708-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | MASSEY VENTURES LIMITED (NZ) | 2023-03-23 | — | — | US | claimed |
| CN-111825636-B | Timolol hydrate and process for preparing same | 武汉科福新药有限责任公司 | 2023-01-20 | — | — | CN | claimed |
| EP-4096648-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | Gillies Mcindoe Research Institute (NZ) | 2022-12-07 | — | — | EP | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| US-20110092507-A1 | Process for preparing R-(+)-3-morpholino-4-(3- tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole | SYN-TECH CHEM. & PHARM. CO., LTD. (TW) | 2011-04-21 | — | — | US | claimed |
| US-4521414-A | 1-TERT-BUTYLAMINO-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)OXY)-2 -PROPANOL AND SALTS THERFOF | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1985-06-04 | — | — | US | claimed |
| WO-2025108987-A1 | COMPOSITIONS AND METHODS FOR TREATING EYETEAR FILM DEFICIENCY AND REDEYE | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-05-30 | — | — | WO | disclosed |
| CN-119302962-A | Pharmaceutical composition containing dextromethorphan maleate, preparation method, pharmaceutical preparation and application thereof | 广州楷石生物科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118813026-A | Water-soluble supramolecular complexes | 博任达生化科技（上海）有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118813027-A | Water-soluble supramolecular complexes | 博任达生化科技（上海）有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-114487076-B | Method for analyzing enantiomer structure of R, S-mandelic acid and derivative thereof | 宁波大学 | 2024-09-17 | — | — | CN | disclosed |
| EP-2964224-B1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2024-07-03 | — | — | EP | disclosed |
| US-7259250-B2 | C-nitroso compounds and use thereof | DUKE UNIVERSITY (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259250-B2 | C-nitroso compounds and use thereof | DUKE UNIVERSITY (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1330425-B1 | C-NITROSO COMPOUNDS AND USE THEREOF | UNIV DUKE (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060276458-A1 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM | 2006-12-07 | — | — | US | disclosed |
| WO-2006124324-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2006-11-23 | — | — | WO | disclosed |
| US-4521414-A | 1-TERT-BUTYLAMINO-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)OXY)-2 -PROPANOL AND SALTS THERFOF | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1985-06-04 | — | — | US | disclosed |
| US-4521414-A | 1-TERT-BUTYLAMINO-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)OXY)-2 -PROPANOL AND SALTS THERFOF | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1985-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276458-A1 | Therapeutic compositions and methods | PDE6H, PDE6C, PDE6D | ADRB2 3390/4885ADRB1 3527/4885CYP1A2 4414/4885 |
| US-20230090708-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | AGTR2, AGTR1, AGT | ADRB2 7/4885ADRB1 15/4885CYP1A2 448/4885 |
| US-20110092507-A1 | Process for preparing R-(+)-3-morpholino-4-(3- tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole | KCNH3, KCNN3, KCNH2 | ADRB2 45/4885ADRB1 29/4885CYP1A2 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.